Yavuz PİRHAN

Evaluation of axillary lymph node status after axillary dissection in patients with SLN negative or single SLN positive T1 and T2 breast cancer

Aim: The most substantial factor determining prognosis in breast cancer is axillary lymph node involvement. Therefore, axillary lymph node status should be evaluated correctly in the staging of the disease and determining the prognosis. In this study, we aim to evaluate the detection rate of metastatic lymph nodes after axillary dissection in patients with negative or single positive sentinel lymph nodes in early-stage breast cancer.Materials and Methods: We have included patients with sentinel lymph node biopsy and/or axillary dissection diagnosed with early-stage (T1 and T2) breast cancer between 2018 and 2019 in the study. We have evaluated tumor prognostic factors from patient files and the total number of lymph nodes and tumor positive lymph nodes from pathology paraffin specimens.Results: The study included 29 female patients with an average age of 56 (34-83). Breast-conserving surgery (BCS)+SLNB was performed in 15 patients and BCS+ AD in 11 patients and modified radical mastectomy (MRM) was performed in 3 patients. In 3 patients with positive surgical margin after BCS + SLN, although one patient was positive and the other two patients were negative in SLN, multiple metasatic lymph nodes were detected after axillary dissection due to the patients' request for axillary dissection. Patients were followed-up for an average of 26 months without recurrence or metastasis. Conclusion: Considering that there may be lymph node metastasis other than the sentinel lymph node in patients with SLNB negatives or single positive sentinel lymph node, we recommend more than one lymph node excision in addition to the stained lymph node.

PDF

___

1. Telli Melinda L, William J, et al. NCCN guidelines updates: breast cancer. J Natl Compr Canc Netw 2019;17:552-5.
2. Stein Roland G, Firicker R. Evaluation of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection for Breast Cancer Treatment Concepts-a Retrospective Study of 1,214 Breast Cancer Patients. Breast Care 2017;12:324-8.
3. Bergkvist L, Frisell J. Multicentre validation study of sentinel node biopsy for staging in breast cancer. British J Surgery 2005;92:1221-4.
4. Chung A, Giuliano AE. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. The Breast Elsevier 2018;1:604-30.e606.
5. Mohammed, Ayad Ahmad. Predictive factors affecting axillary lymph node involvement in patients with breast cancer in Duhok: cross-sectional study. Annals of Med and Surgery 1999;44:87-90.
6. Noguchi, Masakuni. Current controversies concerning sentinel lymph node biopsy for breast cancer. Breast Cancer Res Treat 2004; 84:261-71.
7. Giuliano Armando E, Kirgen DM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391.
8. Sakorafas George H, Adelais G, et al. Axillary lymph node dissection in breast cancer: current status and controversies, alternative strategies and future perspectives. Acta Oncologica 2000;39:455-66.
9. Flett MM, Going JJ, Stanton PD,et al. Sentinel node localization in patients with breast cancer. British J of surgery 1998;85: 991-3.
10. Goyal A, Newcombe RG, Chhabra A, et al. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer–results of the ALMANAC validation phase. Breast Cancer Res Treat 2006;99:203-8.
11. Veronesi U, Galimberti V, Paganelli G, et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 2009;45:1381-8.
12. Krag DN, Anderson SJ, Julian TB, et al. Sentinellymph- node resection compared with conventional axillary-lymph-node dissection in clinically nodenegative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The Lancet Oncology 2010;11:927-33.
13. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010;251: 595-600.
14. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst Monogr 2006;98:599-609.
15. Kern, Kenneth A. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg 1999;189: 539-45.
16. Cody III HS, Hill AD, Tran KN, et al. Credentialing for breast lymphatic mapping: how many cases are enough?. Ann Surg 1999;229:723.